CERTARA

Clinical Trial Outcomes Databases



Certara's Intuitive Clinical Outcomes Database Explorer (CODEx) Interface

Certara's data science team leverages over 15 years of experience exploring and analyzing publicly available data for the world's leading pharmaceutical companies to offer a library of analysis-ready Clinical Trial Outcomes Databases in more than 40 therapeutic areas.

These databases capture up-to-date information on trial design, patient characteristics, treatments, statistical analyses and results (efficacy/safety). Certara provides custom curation to integrate this data with client proprietary data (from CSRs) or convert to client specific formats.

With the addition of an intuitive, web-based graphical interface (CODEx), Certara makes the richness and complexity of public and proprietary data accessible to a broad audience of professionals within pharmaceutical companies. Our goal is to enable drug companies of all sizes to harness the most relevant, reliable data available for key development and commercial decisions much earlier in the process.

The Value of Comparator Data

Maximizing the probability of a drug's success requires making critical decisions throughout its development. Success depends not only on the drug's performance on its own, but also within the competitive landscape. This requires assessing the competition. Further, comparative effectiveness and the systematic review of existing clinical trial and study data is becoming an increasingly critical component to ensuring market success.

Certara's analysis-ready Clinical Trial Outcomes Databases leverage valuable external data to provide key drug development insights:

- Comparative efficacy/safety
- Scaling of endpoints and subpopulations
- Trial design optimization
- Commercial viability

Clinical Trial Outcomes Databases enable Certara's Analytical Laser division to service HEOR customers for all evidence synthesis needs.

- Our clinical trial safety and outcomes data in key areas support market assessments and HTA submissions
- Certara databases are in line with PRISMA systematic review protocols
- Analytica Laser's *ad hoc* literature review services, coupled with Certara databases, support the full range of clients' HEOR and market access needs

Databases Available for Major Therapeutic Areas

CV & Metabolic

- AF Stroke Prevention
- Anticoagulants (Orthopedic Surgery)
- Chronic Kidney Disease
- Dyslipedemia
- Heart Failure
- NASH
- Obesity
- Secondary Stroke Prevention
- T1DM & T2DM

Immunology

- Ankylosing Spondylitis
- Crohn's Disease
- Multiple Sclerosis
- Myasthenia Gravis
- Psoriatic Arthritis and Psoriasis
- Rheumatoid Arthritis
- Sjrogen's Disease
- Lupus
- Ulcerative Colitis

Oncology

- Acute-lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Melanoma (PD1)
- Metastatic Breast Cancer
- Multiple Myeloma
- Non-small Cell Lung Cancer
- Non-Hodgkin's Lymphoma
- Small Cell Lung Cancer
- Solid Tumors (PD1)

CNS, Pain, & Other

- Alzheimer's
- AMD
- Asthma
- Chronic Pain
- Cystic Fibrosis
- Glaucoma
- HBV
- HCV
- Idiopathic Pulmonary Fibrosis
- Major Depression
- Migraine
- Narcolepsy
- Neuropathic Pain
- Osteoporosis
- Pulmonary Arterial Hypertension
- Schizophrenia

Database Example: NSCLC

The Certara NSCLC Database contains publically available information from clinical trials on drugs that are either on the market or in development for the treatment of non-small cell lung cancer (NSCLC).

Parameter	Description
format	Excel or CODEx
indications	nsclc
references	709
trials	683
trial.arms	1,260
patients	157,154
data.rows	68,609
compounds	all systemic pharmacological treatments
key.efficacy.endpoints	anemia, cr, dcr, dor, dor median, leukopenia, lymphopenia, neutropenia, neutropenia febrile, orr, os, os median, pd, pfs, pfs median, pr, rfs, rfs median, sd, thrombocytopenia, ttf, ttf median, ttp, ttp median, ttr median, wbc count
key.safety.endpoints	alopecia, arthralgia, arthralgia/myalgia, death, diarrhea, dropout, dropout ae, dyspnea, fatigue, myalgia, nausea, nausea/vomiting, neuropathy, peripheral motor neuropathy, peripheral neuropathy, peripheral sensory neuropathy, vomiting

Customers can readily access Certara databases centrally through our integrated Clinical Outcomes Database Explorer (CODEx) interface to visualize, explore, analyze, and communicate database content:

- **Gateway to clinical trial data repository.** CODEx provides access to the most current, publicly available trial information contained in our databases allowing users to scope specific drug development decisions related to study design, patient populations, and dose levels.
- **Exploratory analysis platform.** CODEx helps users visualize endpoint and subpopulation relationships and other key trial data to provide early insight during drug development.
- **Communication and visualization tool.** Users can interact, plot, and summarize data in real time to share results with colleagues, stimulate ideas, and help inform key decisions.

For additional information on Certara's Clinical Trial Outcomes Databases, our CODEx application and to schedule a demo or free trial, contact:

Nancy.Zhang@Certara.com Tel: 510-551-6335

About Certara

Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. Certara's solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies.

For more information visit www.certara.com or email sales@certara.com.

BR Sep 2018 v1 092618